Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Skin hyperpigmentation
ADR ID BADD_A04040
ADR Hierarchy
23      Skin and subcutaneous tissue disorders
23.05      Pigmentation disorders
23.05.01      Hyperpigmentation disorders
23.05.01.003      Skin hyperpigmentation
Description A disorder characterized by darkening of the skin due to excessive melanin deposition. [CTCAE] Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis. Hyperpigmentation can be localized or generalized. The condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance. [MeSH]
MedDRA Code 10040865
MeSH ID D017495
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE)
Synonym
Hyperpigmentation skin | Skin hyperpigmentation | Hypermelanosis | Hyperpigmentation of palms | Palmoplantar hyperpigmentation | Increased skin pigmentation | Periorbital hyperpigmentation | Hyperpigmentation | Hypermelanoses
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00490Clobetasol propionate--
BADD_D00495Clofarabine--
BADD_D00502Clonidine--
BADD_D00534Cosyntropin--
BADD_D00549Cyclophosphamide--
BADD_D00551Cyclosporine0.000751%
BADD_D00580Dapsone0.000367%
BADD_D00590Daunorubicin--
BADD_D00605Demeclocycline--
BADD_D00609Deoxycholic acid0.000993%
BADD_D00623Dexamethasone--
BADD_D00624Dexamethasone phosphate--
BADD_D00653Diclofenac0.000056%
BADD_D00674Diltiazem--
BADD_D00675Diltiazem hydrochloride--
BADD_D00699Docetaxel--
BADD_D00723Doxorubicin0.000302%
BADD_D00749Efavirenz--
BADD_D00765Empagliflozin0.000200%
BADD_D00766Emtricitabine--
BADD_D00784Epirubicin--
BADD_D00785Epirubicin hydrochloride--
BADD_D00800Erlotinib--
BADD_D00821Estradiol--
BADD_D00844Ethinyl estradiol--
BADD_D00850Etodolac--
BADD_D00852Etonogestrel0.001152%
BADD_D00873Fenofibrate0.000039%
BADD_D00886Ferrosoferric oxide--
BADD_D00908Floxuridine--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
ADR Term Drug Name Target